US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Aardvark Therapeutics, Inc. - Common Stock
(NQ:
AARD
)
4.450
-0.310 (-6.51%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aardvark Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
Today 11:37 EDT
Pension funds, asset managers, and other fiduciaries holding Aardvark Therapeutics, Inc. (NASDAQ: AARD) positions acquired in or after the February 2025 IPO may wish to evaluate lead plaintiff options,...
From
Levi & Korsinsky, LLP
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Today 10:30 EDT
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your Behalf
October 10, 2026
From
Grabar Law Office
Via
GlobeNewswire
URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
October 10, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
October 09, 2026
AARD INVESTOR ALERT
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 08, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your
October 08, 2026
From
Grabar Law Office
Via
GlobeNewswire
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
October 08, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
AARD Deadline: Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
October 07, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law
October 06, 2026
From
Grabar Law Office
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
October 05, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses
October 05, 2026
San Diego, California--(Newsfile Corp. - October 5, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class...
Via
Newsfile
Topics
Initial Public Offering
Lawsuit
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 05, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL); Ardelyx, Inc. (NASDAQ: ARDX); Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI): Grabar Law Office is Investigating
October 05, 2026
From
Grabar Law Office
Via
GlobeNewswire
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD
October 02, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
October 02, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 01, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
September 30, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
September 30, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AARDVARK DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD
September 28, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 28, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 24, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)
September 24, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
September 22, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is
September 22, 2026
From
Grabar Law Office
Via
GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
September 21, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
